Date |
Symbol |
Description |
Type |
Disease |
Designation |
Success Rating |
H2 2016
|
TBPH |
|
Phase 2a Results |
Infectious Disease |
None |
|
Q4 2016
|
BLUE |
|
Phase 1/2 Results |
Other |
Breakthrough Therapy |
|
Q4 2016
|
BLUE |
|
Phase 1/2 Results |
Other |
None |
|
Q4 2016
|
CYCC |
|
Phase 3 Results |
Oncology |
Orphan Drug |
|
Not General
|
INFI |
|
Phase 3 Results |
Oncology |
Fast Track |
|
Q4 2016
|
EIGR |
|
Phase 2 Results |
Other |
None |
|
Q4 2016
|
ACAD |
|
Phase 2 Results |
Neurology |
None |
|
Q4 2016
|
ACHN |
|
Phase 2 Results |
Other |
None |
|
H2 2016
|
ACOR |
|
Phase 3 Results |
Neurology |
None |
|
H2 2016
|
ADMS |
|
NDA Submission |
Neurology |
Orphan Drug |
|